• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.用肺炎球菌蛋白PsaA和PspA的混合物对小鼠进行鼻内免疫，对肺炎链球菌的鼻咽部定植具有高度保护作用。
Infect Immun. 2000 Feb;68(2):796-800. doi: 10.1128/IAI.68.2.796-800.2000.
2
The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.使用蛋白质疫苗预防肺炎链球菌引起的中耳炎的可能性。
Vaccine. 2000 Dec 8;19 Suppl 1:S87-95. doi: 10.1016/s0264-410x(00)00285-1.
3
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.用肺炎球菌表面蛋白A（PspA）对小鼠进行鼻内免疫可预防肺炎链球菌的鼻内定植、肺部感染和败血症。
J Infect Dis. 1997 Apr;175(4):839-46. doi: 10.1086/513980.
4
Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.含PsaA和PspA片段的融合蛋白引发的保护性免疫反应。
Immunol Invest. 2015;44(5):482-96. doi: 10.3109/08820139.2015.1037956.
5
Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.肺炎链球菌表面蛋白A（PpmA）、表面蛋白A（PsaA）和表面蛋白A（PspA）的表面可及性与抗体介导的全身性感染免疫之间的关系。
Infect Immun. 2005 Mar;73(3):1304-12. doi: 10.1128/IAI.73.3.1304-1312.2005.
6
PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae.肺炎球菌表面黏附素A（PsaA）和肺炎球菌表面蛋白A（PspA）DNA疫苗可诱导针对肺炎链球菌的体液免疫和细胞免疫反应。
Vaccine. 2001 Dec 12;20(5-6):805-12. doi: 10.1016/s0264-410x(01)00395-4.
7
Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children.儿童腺样体B细胞对新型肺炎球菌蛋白肺炎溶血素、肺炎球菌表面蛋白A、肺炎球菌表面黏附素A和胆碱结合蛋白A的免疫反应。
Infect Immun. 2002 Oct;70(10):5363-9. doi: 10.1128/IAI.70.10.5363-5369.2002.
8
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.利用肺炎球菌表面蛋白A（PspA）和其他肺炎球菌蛋白引发针对肺炎球菌感染的保护作用的潜力。
Vaccine. 2000 Feb 25;18(16):1707-11. doi: 10.1016/s0264-410x(99)00511-3.
9
Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.与其他四种佐剂相比，用 PsaA-PspA 融合蛋白和 AS02 作为佐剂进行免疫接种后，对致死性肺炎球菌攻击的保护作用最强。
Med Microbiol Immunol. 2019 Apr;208(2):215-226. doi: 10.1007/s00430-019-00579-9. Epub 2019 Feb 1.
10
Systemic and mucosal protective immunity to pneumococcal surface protein A.针对肺炎球菌表面蛋白A的全身及黏膜保护性免疫
Ann N Y Acad Sci. 1996 Oct 25;797:118-26. doi: 10.1111/j.1749-6632.1996.tb52954.x.

引用本文的文献

1
serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?南亚低收入和中等收入国家的血清型分布：我们是否需要重新审视肺炎球菌疫苗策略？
Hum Vaccin Immunother. 2025 Dec;21(1):2461844. doi: 10.1080/21645515.2025.2461844. Epub 2025 Feb 25.
2
Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections.表达肺炎球菌表面蛋白A的鼻内流感载体疫苗可预防流感和肺炎链球菌感染。
NPJ Vaccines. 2024 Dec 19;9(1):246. doi: 10.1038/s41541-024-01033-5.
3
Trivalent immunization with metal-binding proteins confers protection against enterococci in a mouse infection model.在小鼠感染模型中，用金属结合蛋白进行三价免疫可提供针对肠球菌的保护作用。
FEMS Microbes. 2024 Oct 3;5:xtae031. doi: 10.1093/femsmc/xtae031. eCollection 2024.
4
Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18-49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.一种新型蛋白质基肺炎球菌疫苗在18-49岁健康成年人中的安全性和免疫原性的初步评估：一项Ia期随机、双盲、安慰剂对照临床研究。
Vaccines (Basel). 2024 Jul 23;12(8):827. doi: 10.3390/vaccines12080827.
5
Biological puzzles solved by using : a historical review of the pneumococcal studies that have impacted medicine and shaped molecular bacteriology.运用历史回顾的方法解决生物学难题：对影响医学和分子细菌学发展的肺炎球菌研究的回顾。
J Bacteriol. 2024 Jun 20;206(6):e0005924. doi: 10.1128/jb.00059-24. Epub 2024 May 29.
6
IL-27 regulates the differentiation of follicular helper NKT cells via metabolic adaptation of mitochondria.IL-27 通过调节线粒体代谢适应来调控滤泡辅助 NKT 细胞的分化。
Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2313964121. doi: 10.1073/pnas.2313964121. Epub 2024 Feb 23.
7
Otitis media: recent advances in otitis media vaccine development and model systems.中耳炎：中耳炎疫苗研发及模型系统的最新进展
Front Microbiol. 2024 Jan 24;15:1345027. doi: 10.3389/fmicb.2024.1345027. eCollection 2024.
8
Recent progress in pneumococcal protein vaccines.肺炎球菌蛋白疫苗的最新进展。
Front Immunol. 2023 Sep 25;14:1278346. doi: 10.3389/fimmu.2023.1278346. eCollection 2023.
9
Virulence factors of - a molecular perspective.-的毒力因子——分子视角
Front Microbiol. 2022 Oct 26;13:1025136. doi: 10.3389/fmicb.2022.1025136. eCollection 2022.
10
Non-capsular based immunization approaches to prevent infection.基于非囊膜的免疫接种方法预防感染。
Front Cell Infect Microbiol. 2022 Sep 26;12:949469. doi: 10.3389/fcimb.2022.949469. eCollection 2022.

本文引用的文献

1
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.肺炎链球菌的pspC基因编码一种多态性蛋白PspC，该蛋白可引发针对PspA的交叉反应性抗体，并为肺炎球菌菌血症提供免疫力。
Infect Immun. 1999 Dec;67(12):6533-42. doi: 10.1128/IAI.67.12.6533-6542.1999.
2
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.七价肺炎球菌CRM197结合疫苗在婴幼儿中的安全性和免疫原性。
Pediatr Infect Dis J. 1999 Sep;18(9):757-63. doi: 10.1097/00006454-199909000-00004.
3
Strategies for the control of pneumococcal diseases.肺炎球菌疾病的控制策略。
Vaccine. 1999 Jul 30;17 Suppl 1:S79-84. doi: 10.1016/s0264-410x(99)00112-7.
4
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.肺炎球菌表面蛋白A抑制肺炎链球菌的补体激活。
Infect Immun. 1999 Sep;67(9):4720-4. doi: 10.1128/IAI.67.9.4720-4724.1999.
5
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.3型肺炎球菌对补体激活和吞噬作用的抗性是由补体调节蛋白H因子的结合介导的。
Infect Immun. 1999 Sep;67(9):4517-24. doi: 10.1128/IAI.67.9.4517-4524.1999.
6
Pneumococcal vaccines: history, current status, and future directions.肺炎球菌疫苗：历史、现状与未来方向。
Am J Med. 1999 Jul 26;107(1A):69S-76S. doi: 10.1016/s0002-9343(99)00105-9.
7
The epidemiology of pneumococcal infection in children in the developing world.发展中世界儿童肺炎球菌感染的流行病学
Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):777-85. doi: 10.1098/rstb.1999.0430.
8
Pneumolysin in pneumococcal adherence and colonization.肺炎链球菌溶血素在肺炎链球菌黏附和定植中的作用
Microb Pathog. 1998 Dec;25(6):337-42. doi: 10.1006/mpat.1998.0239.
9
The crystal structure of pneumococcal surface antigen PsaA reveals a metal-binding site and a novel structure for a putative ABC-type binding protein.肺炎球菌表面抗原PsaA的晶体结构揭示了一个金属结合位点和一种假定的ABC型结合蛋白的新结构。
Structure. 1998 Dec 15;6(12):1553-61. doi: 10.1016/s0969-2126(98)00153-1.
10
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.一种针对肺炎球菌表面蛋白A的黏膜免疫无毒佐剂。
J Immunol. 1998 Oct 15;161(8):4115-21.

用肺炎球菌蛋白PsaA和PspA的混合物对小鼠进行鼻内免疫，对肺炎链球菌的鼻咽部定植具有高度保护作用。

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

作者信息

Briles D E, Ades E, Paton J C, Sampson J S, Carlone G M, Huebner R C, Virolainen A, Swiatlo E, Hollingshead S K

机构信息

Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

出版信息

Infect Immun. 2000 Feb;68(2):796-800. doi: 10.1128/IAI.68.2.796-800.2000.

DOI:10.1128/IAI.68.2.796-800.2000
PMID:10639448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC97207/
Abstract

Acquisition of pneumococci is generally from carriers rather than from infected individuals. Therefore, to induce herd immunity against Streptococcus pneumoniae it will be necessary to elicit protection against carriage. Capsular polysaccharide-protein conjugates, PspA, and PsaA are known to elicit some protection against nasopharyngeal carriage of pneumococci but do not always completely eliminate carriage. In this study, we observed that PsaA elicited better protection than did PspA against carriage. Pneumolysin elicited no protection against carriage. Immunization with a mixture of PsaA and PspA elicited the best protection against carriage. These results indicate that PspA and PsaA may be useful for the elicitation of herd immunity in humans. As PspA and pneumolysin are known to elicit immunity to bacteremia and pneumonia, their inclusion in a mucosal vaccine may enable such a vaccine to prevent invasive disease as well as carriage.

摘要

肺炎球菌的获得通常来自携带者而非感染者。因此，要诱导针对肺炎链球菌的群体免疫，有必要引发针对携带状态的保护作用。已知荚膜多糖 - 蛋白结合物、肺炎球菌表面蛋白A（PspA）和肺炎球菌表面黏附素A（PsaA）可引发针对肺炎球菌鼻咽部携带的一定保护作用，但并不总能完全消除携带状态。在本研究中，我们观察到PsaA相较于PspA对携带状态引发了更好的保护作用。肺炎溶血素对携带状态未引发保护作用。用PsaA和PspA的混合物进行免疫接种对携带状态引发了最佳保护作用。这些结果表明，PspA和PsaA可能有助于在人类中引发群体免疫。由于已知PspA和肺炎溶血素可引发针对菌血症和肺炎的免疫，将它们纳入黏膜疫苗可能使这种疫苗既能预防侵袭性疾病又能预防携带状态。